Similarly, it has been reported that disruption of VLA-5 function in BCR-ABL1+ leukemic cells using anti-VLA-5 inhibitory antibodies could significantly delay B-ALL engraftment in a xenograft mouse model and act synergistically with imatinib to induce malignant cell apoptosis in vitro [116]. Here, ITGA5 is linked to acute lymphoblastic leukemia.